Danielle Golovin

Florida

I love science, art, education, animals, board games, cooking and volleyball. Central Michigan (B.S.) and Vanderbilt University (Ph.D.) alum.

Featured in: Favicon

biocentury.com Favicon

zephyrnet.com

Articles

Science Spotlight: Balancing safety and efficacy with dual TCR/CAR T cells

1 week ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes microglia replacement for neurological disorders and enhanced mRNA vaccine efficacy By Danielle Golovin, Senior Biopharma Analyst A team of scientists, mostly from the National Cancer Institute, created dual TCR/CAR T cells that killed tumors with minimal toxicity to healthy tissue, a problem that has limited CAR T cell applicability to solid tumors.
Insight into ovarian cancer treatment resistance: Literature Dive

1 week ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationFour tumor atlases point to target vulnerabilities and predictive signatures in epithelial ovarian cancers By Danielle Golovin, Senior Biopharma AnalystFour studies characterizing the molecular landscape of epithelial ovarian cancers describe molecular signatures that predict patient outcomes, and highlight potential mechanisms of resistance and response to chemotherapy and immunotherapy.
Radiant: Taking valency and multi-specificity up several notches

2 weeks ago | biocentury.com | Danielle Golovin

ARTICLE | Emerging Company ProfileCanadian start-up’s self-assembling scaffold creates high avidity antibodies against challenging targets By Danielle Golovin, Senior Biopharma AnalystBy connecting two dozen antibody fragments to a single scaffold, Radiant’s platform creates therapies with dramatically stronger binding than traditional mAbs, enabling the Toronto-based company to go after difficult targets that require clustering for activation or inhibition.
Science Spotlight: Ultrasound-controlled CAR T cells

3 weeks ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes a protein conjugation strategy, a SMURF1 inhibitor for hypertension, and more By Danielle Golovin, Senior Biopharma AnalystA team led by Acoustic Cell Therapy Inc. co-founder Yingxiao Wang developed CAR T cells that are only activated locally with focused ultrasound, reducing off-tumor toxicity and CAR T exhaustion.
Freya: Restoring microbial balance in the reproductive tract

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Emerging Company ProfileShifting the inflammatory vaginal microbiome back to a healthy, Lactobacillus-dominant one By Danielle Golovin, Senior Biopharma AnalystFreya is leveraging learnings from clinical trials of vaginal microbiome transplants to develop bacterial products that reduce local inflammation and support healthy pregnancies. The company was born out of the gut microbiome boom. “In the last 10 years, there’s been quite a lot of progress in the gut microbiome space.
Base editor efficiency boom. China leading charge?

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationRecently published studies reveal advances in precision and performance, driven largely by labs in China By Danielle Golovin, Senior Biopharma AnalystAn analysis of more than a dozen recent papers highlights momentum in improving the efficiency of DNA and RNA base editors, and reveals major contributions by Chinese researchers.
Science Spotlight: A FOXP3 regulator to enhance induced Tregs

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more By Danielle Golovin, Senior Biopharma AnalystA suppressor of the regulatory T cell master transcription factor FOXP3 identified by the lab of Treg pioneer Shimon Sakaguchi and collaborators at Chugai Pharmaceutical Co. Ltd.
Exosomes are finding new life as the field solves for manufacturing

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Product DevelopmentCan exosomes step in as delivery vehicles where LNPs fall short? By Danielle Golovin, Senior Biopharma AnalystThe sky is starting to clear around exosome therapies after a series of setbacks and technical hurdlesraised doubts about the technology.
Science Spotlight: New insight into LAG3’s checkpoint function

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos By Danielle Golovin, Senior Biopharma Analyst Beigene Ltd. (NASDAQ:ONC; HKEX:6160) and collaborators at Shanghaitech University unraveled the mechanism of LAG3’s immune checkpoint function, which could have implications for designing antibodies that block LAG3 or predicting patient response.
Solving CNS delivery will open big doors for epigenome editing: a Perspective

1 month ago | biocentury.com | Danielle Golovin

ARTICLE | Editor's CommentaryEpigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery By Danielle Golovin, Senior Biopharma AnalystEpigenome editing companies could bring big benefits to patients and, in some cases, have entire markets to themselves, if they set their sights on neurological diseases. Most, however, are starting in the less risky territory of validated targets for liver diseases.